European Society of Cardiology

LONDON — The European Society of Cardiology Congress featured several presentations on the optimal patient populations and duration for dual antiplatelet therapy in patients with ACS or stable CAD.

LONDON — In the RE-LY trial, the use of nonsteroidal anti-inflammatory drugs was linked to increased bleeding risk and a higher rate of hospitalizations, according to research presented at the European Society of Cardiology Congress.

LONDON — Drinking more than four cups of caffeinated coffee per day was associated with a fourfold higher risk for MI, stroke, peripheral artery disease and kidney failure among young adults with untreated stage 1 hypertension, according to research presented at the European Society of Cardiology Congress.

LONDON — The use of gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in patients with HF with reduced ejection fraction, according to data presented at the European Society of Cardiology Congress.

LONDON — Trypanocidal therapy with benznidazole in patients with established Chagas’ cardiomyopathy did not reduce cardiac deterioration, despite a reduction in serum parasite detection, according to 5-year data from the BENEFIT study.

LONDON — Analyses from the IMPROVE-IT study presented at the European Society of Cardiology Congress indicated that adding ezetimibe to simvastatin especially benefited patients with diabetes and did not cause new-onset diabetes.

LONDON — Peri-infarct pacing did not prevent left ventricular remodeling or improve outcomes during 18 months of follow-up in patients with large first MI, according to data from the PRomPT study.

LONDON — The 5-year results of the EXAMINATION trial, presented at the European Society of Cardiology Congress, indicated that an everolimus-eluting stent had superior clinical outcomes to a bare-metal stent in patients with STEMI.

LONDON — At 5 years, patients with paroxysmal atrial fibrillation assigned catheter ablation were more likely to be free from recurrent atrial fibrillation than those assigned antiarrhythmic drugs, according to new data from the MANTRA-PAF study.

LONDON — Patients with heterozygous familial hypercholesterolemia assigned the PCSK9 inhibitor alirocumab had significant lowering of LDL at 78 weeks, according to results from four 18-month placebo-controlled studies.